Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eagle Pharmaceuticals (EGRX)

Eagle Pharmaceuticals (EGRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 55,454
  • Shares Outstanding, K 12,987
  • Annual Sales, $ 316,610 K
  • Annual Income, $ 35,640 K
  • 60-Month Beta 0.53
  • Price/Sales 0.22
  • Price/Cash Flow 1.17
  • Price/Book 0.23
Trade EGRX with:

Options Overview Details

View History
  • Implied Volatility 108.97% ( +7.14%)
  • Historical Volatility 78.86%
  • IV Percentile 31%
  • IV Rank 28.71%
  • IV High 326.34% on 08/15/24
  • IV Low 21.43% on 10/16/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 8
  • Volume Avg (30-Day) 51
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 1,257
  • Open Int (30-Day) 787

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.55 +18.31%
on 09/12/24
5.45 -22.94%
on 08/29/24
-0.38 (-8.30%)
since 08/20/24
3-Month
3.55 +18.31%
on 09/12/24
6.37 -34.07%
on 07/09/24
+0.13 (+3.19%)
since 06/20/24
52-Week
3.21 +30.84%
on 05/29/24
15.91 -73.61%
on 09/29/23
-11.01 (-72.39%)
since 09/20/23

Most Recent Stories

More News
Eagle Pharmaceuticals: Q2 Earnings Snapshot

Eagle Pharmaceuticals: Q2 Earnings Snapshot

EGRX : 4.20 (-1.64%)
Eagle Pharmaceuticals: Q1 Earnings Snapshot

Eagle Pharmaceuticals: Q1 Earnings Snapshot

EGRX : 4.20 (-1.64%)
Eagle Pharmaceuticals: Q4 Earnings Snapshot

Eagle Pharmaceuticals: Q4 Earnings Snapshot

EGRX : 4.20 (-1.64%)
Eagle Pharmaceuticals: Q3 Earnings Snapshot

Eagle Pharmaceuticals: Q3 Earnings Snapshot

EGRX : 4.20 (-1.64%)
Eagle Pharmaceuticals (EGRX) Q2 2022 Earnings Call Transcript

EGRX earnings call for the period ending June 30, 2022.

EGRX : 4.20 (-1.64%)
Eagle Pharmaceuticals Reports Second Quarter 2022 Results

•   Q2 2022 net loss was $(0.74) per basic and diluted share and adjusted non-GAAP net income was $1.58 per basic and $1.56 per diluted share •   Total...

EGRX : 4.20 (-1.64%)
Eagle Pharmaceuticals Takes Equity Stake in, with Option to Acquire, Enalare Therapeutics to Advance Global Development of ENA-001, a Novel Agnostic Respiratory Stimulant

-- ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity -- -- Approval for...

EGRX : 4.20 (-1.64%)
Eagle Pharmaceuticals Appoints Debra M. Hussain as SVP, Head of Commercial

WOODCLIFF LAKE, N.J., July 18, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the...

EGRX : 4.20 (-1.64%)
Eagle Pharmaceuticals Completes Acquisition of Acacia Pharma Group plc, Expanding Acute Care Footprint

Adds two U.S. Food and Drug Administration (“FDA”) approved new chemical entities with strong patent protectionBARHEMSYS® (amisulpride for injection) and...

EGRX : 4.20 (-1.64%)
Eagle Pharmaceuticals Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, a Beta-1 Adrenergic Blocker

-- Submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial...

EGRX : 4.20 (-1.64%)

Business Summary

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102,...

See More

Key Turning Points

3rd Resistance Point 4.72
2nd Resistance Point 4.63
1st Resistance Point 4.45
Last Price 4.20
1st Support Level 4.18
2nd Support Level 4.09
3rd Support Level 3.91

See More

52-Week High 15.91
Fibonacci 61.8% 11.06
Fibonacci 50% 9.56
Fibonacci 38.2% 8.06
Last Price 4.20
52-Week Low 3.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar